{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:27:52Z","timestamp":1793410072638,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and main results<\/jats:title><jats:p>Among 113\u2009353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p&lt;0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p&lt;0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p&lt;0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.<\/jats:p><\/jats:sec>","DOI":"10.1136\/thorax-2024-222113","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T16:10:27Z","timestamp":1735229427000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease"],"prefix":"10.1136","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-4751","authenticated-orcid":false,"given":"Anne E","family":"Ioannides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-5421","authenticated-orcid":false,"given":"Constantinos","family":"Kallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7705-0300","authenticated-orcid":false,"given":"Hannah R","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0149-4869","authenticated-orcid":false,"given":"Jennifer K","family":"Quint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,25]]},"reference":[{"key":"2025011705101017000_80.2.67.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212514"},{"key":"2025011705101017000_80.2.67.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2018.09.006"},{"key":"2025011705101017000_80.2.67.3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0057-2018"},{"key":"2025011705101017000_80.2.67.4","doi-asserted-by":"crossref","unstructured":"Morgan AD , Zakeri R , Quint JK . Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12. doi:10.1177\/1753465817750524","DOI":"10.1177\/1753465817750524"},{"key":"2025011705101017000_80.2.67.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136077"},{"key":"2025011705101017000_80.2.67.6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-6-200809160-00004"},{"key":"2025011705101017000_80.2.67.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.3.640"},{"key":"2025011705101017000_80.2.67.8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.15326\/jcopdf.2022.0386","article-title":"Inhaled Corticosteroids and Risk of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Regression","volume":"10","author":"Gadhvi","year":"2023","journal-title":"J COPD F"},{"key":"2025011705101017000_80.2.67.9","article-title":"Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis","volume":"2018","author":"Jing","year":"2018","journal-title":"Can Respir J"},{"key":"2025011705101017000_80.2.67.10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/COPD.S6942","article-title":"An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease","volume":"5","author":"Singh","year":"2010","journal-title":"COPD"},{"key":"2025011705101017000_80.2.67.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.07.015"},{"key":"2025011705101017000_80.2.67.12","unstructured":"Clinical Practice Research Datalink . PRD aurum may 2022 (version 2022.05.001). Clinical Practice Research Datalink; 2022. Available: https:\/\/doi.org\/10.48329\/t89s-kf12"},{"key":"2025011705101017000_80.2.67.13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025011705101017000_80.2.67.14","unstructured":"Clinical Practice Research Datalink . Clinical Practice Research Datalink; CPRD Aurum HES APC January 2022 (Version 2022.01.001), 2022. Available: https:\/\/doi.org\/10.48329\/VAGX-9D96"},{"key":"2025011705101017000_80.2.67.15","unstructured":"Clinical Practice Research Datalink . CPRD aurum small area data (patient) January 2022 (version 2022.01.001). Clinical Practice Research Datalink; 2022. Available: https:\/\/doi.org\/10.48329\/AYTT-H222"},{"key":"2025011705101017000_80.2.67.16","unstructured":"Clinical Practice Research Datalink . CPRD aurum ons deaths January 2022 (version 2022.01.001). Clinical Practice Research Datalink; 2022. Available: https:\/\/doi.org\/10.48329\/Q34F-F505"},{"key":"2025011705101017000_80.2.67.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005540","article-title":"Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD)","volume":"4","author":"Quint","year":"2014","journal-title":"BMJ Open"},{"key":"2025011705101017000_80.2.67.18","doi-asserted-by":"publisher","DOI":"10.1159\/000515133"},{"key":"2025011705101017000_80.2.67.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128806"},{"key":"2025011705101017000_80.2.67.20","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S114554"},{"key":"2025011705101017000_80.2.67.21","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12067"},{"key":"2025011705101017000_80.2.67.22","unstructured":"Lodise TP , Li J , Gandhi HN , et al . Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies"},{"key":"2025011705101017000_80.2.67.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.11.007"},{"key":"2025011705101017000_80.2.67.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202006-2618OC"},{"key":"2025011705101017000_80.2.67.25","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01777-x"},{"key":"2025011705101017000_80.2.67.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128008"},{"key":"2025011705101017000_80.2.67.27","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2020.1787369"},{"key":"2025011705101017000_80.2.67.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2012.05.008"},{"key":"2025011705101017000_80.2.67.29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/COPD.S31236","article-title":"The association between COPD and heart failure risk: a review","volume":"8","author":"de Miguel D\u00edez","year":"2013","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025011705101017000_80.2.67.30","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1312-7"},{"key":"2025011705101017000_80.2.67.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2019-000470","article-title":"Coronary heart disease and heart failure in asthma, COPD and asthma-COPD overlap","volume":"7","author":"Ingebrigtsen","year":"2020","journal-title":"BMJ Open Respir Res"},{"key":"2025011705101017000_80.2.67.32","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S200919"},{"key":"2025011705101017000_80.2.67.33","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.020180"},{"key":"2025011705101017000_80.2.67.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00095909"},{"key":"2025011705101017000_80.2.67.35","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216390"},{"key":"2025011705101017000_80.2.67.36","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002142","article-title":"Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK","volume":"9","author":"Sundaram","year":"2022","journal-title":"Open Heart"},{"key":"2025011705101017000_80.2.67.37","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad078","article-title":"Determining prescriptions in electronic healthcare record data: methods for development of standardized, reproducible drug codelists","volume":"6","author":"Graul","year":"2023","journal-title":"JAMIA Open"},{"key":"2025011705101017000_80.2.67.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151357","article-title":"Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records","volume":"11","author":"Rothnie","year":"2016","journal-title":"PLoS ONE"},{"key":"2025011705101017000_80.2.67.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74854-8"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2024-222113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T13:10:54Z","timestamp":1737119454000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2024-222113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,25]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/thorax-2024-222113"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2024-222113","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,25]]}}}